Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deborah Stokes

Neurology Tifton, GA Doctor of Osteopathy

NPI 1538146956 CMS profile 342219

2227 US Highway 41 N, Tifton, GA 31794

Open in the dashboard

General payments

$5,422

303 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deborah Stokes of Tifton, GA is reported in the CMS Open Payments database as having received $5,422 across 303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $590 22
2024 General $832 39
2023 General $457 22
2022 General $397 21
2021 General $686 44
2020 General $902 58
2019 General $1,558 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deborah Stokes
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Deborah Stokes were reported at $590. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Deborah Stokes Neurology median Middle half National median
2019 $1,558 $474 $118–$2,177 $163
2020 $902 $367 $82–$2,309 $114
2021 $686 $438 $104–$2,547 $132
2022 $397 $442 $103–$2,388 $149
2023 $457 $464 $119–$2,312 $160
2024 $832 $468 $119–$2,323 $164
2025 $590 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $421 22 payments
  2. Allergan Inc. $405 30 payments
  3. Lilly USA, LLC $305 15 payments
  4. Neurocrine Biosciences, Inc. $299 13 payments
  5. Biogen, Inc. $294 21 payments
  6. Eisai Inc. $291 17 payments
  7. Novartis Pharmaceuticals Corporation $290 14 payments
  8. Adamas Pharmaceuticals, Inc. $290 21 payments
  9. Neurelis, Inc. $274 15 payments
  10. Alexion Pharmaceuticals, Inc. $252 11 payments
  11. Other $2,302 124 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,187 294 payments
  2. Education $123 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $112 6 payments
Products named General payments · program years 2019–2025
  1. BOTOX $328 24 payments
  2. Briviact $326 16 payments
  3. GOCOVRI $290 21 payments
  4. INGREZZA $284 12 payments
  5. VALTOCO $274 15 payments
  6. Fycompa $269 16 payments
  7. AIMOVIG $233 13 payments
  8. TYSABRI $226 17 payments
  9. OCREVUS $195 10 payments
  10. ULTOMIRIS $179 8 payments
  11. Other $3,325 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,728

Median for Neurology: 833

Drug cost

$152,463

Median for Neurology: $202,670

Branded share of claims

18.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Copaxone Glatiramer Acetate Brand 11 $64,152
Briviact Brivaracetam Brand 18 $21,588
Fycompa Perampanel Brand 14 $15,738
Levetiracetam Generic 272 $7,047
Memantine Hcl Er Memantine Hcl Brand 55 $5,883
Oxcarbazepine Generic 59 $5,731
Rivastigmine Generic 25 $5,554
Carbidopa-Levodopa Carbidopa/Levodopa Brand 170 $4,354
Memantine Hcl Generic 247 $3,696
Carbatrol Carbamazepine Brand 11 $2,753

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$14,967

Medicare's payments for the services billed

Medicare patients

115

Average age 72

Services billed

233

74 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 38%
Alzheimer's or dementia 29%
Depression 27%
Ischemic heart disease 26%
Chronic kidney disease 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $95
$95 — —
APTIOM
  • Sumitomo Pharma America, Inc. $76
$76 — —
VALTOCO
  • Neurelis, Inc. $72
$72 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $68
$68 — —
Briviact
  • UCB, Inc. $58
$58 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record